Cargando…
Targeted therapy in lymphoma
Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discov...
Autores principales: | Johnston, Patrick B, Yuan, RuiRong, Cavalli, Franco, Witzig, Thomas E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003620/ https://www.ncbi.nlm.nih.gov/pubmed/21092307 http://dx.doi.org/10.1186/1756-8722-3-45 |
Ejemplares similares
-
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
por: Yuan, RuiRong, et al.
Publicado: (2009) -
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022) -
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016) -
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021) -
Novel targeted therapies of T cell lymphomas
por: Iżykowska, Katarzyna, et al.
Publicado: (2020)